2023 World Conference on Lung Cancer (Posters)-P1.25. Enhanced Assessment Of Recurrence Risk Of Stage I NSCLC By Combined Adenocarcinoma Grading System And Serum Proteomic Testing

P1.25. Enhanced Assessment Of Recurrence Risk Of Stage I NSCLC By Combined Adenocarcinoma Grading System And Serum Proteomic Testing - PDF(Abstract)

Back to course

Pdf Summary

This presentation discusses the enhanced assessment of recurrence risk for patients with stage I non-small cell lung cancer (NSCLC) using a combined adenocarcinoma grading system and serum proteomic testing. The study aims to improve the stratification of recurrence risk, allowing for better personalized treatment protocols. <br /><br />The researchers used mass spectrometry to profile the circulating proteome of 310 patients with early-stage NSCLC from New York University. Machine learning was then used to combine the mass spectral data and create a ternary recurrence risk stratification test. This test was validated in two independent cohorts of patients with stage I NSCLC from NYU and Rush University Medical Center. <br /><br />The results showed that the proteomic test stratified patients into three groups with low, intermediate, and high recurrence risk. The 3-year recurrence-free percentage ranged from 63% to 98% in the different risk groups. Additionally, when the proteomic classification was combined with the adenocarcinoma grading system, the risk assessment was improved compared to using either method alone. <br /><br />In conclusion, the study demonstrates that pre-surgery serum proteomic testing can accurately assess the recurrence risk for patients with resectable stage I NSCLC. Furthermore, combining this information with the tumor grading system for patients with adenocarcinoma improves the prediction of recurrence risk. This research has the potential to help guide treatment decisions and improve outcomes for patients with early-stage NSCLC.

Asset Subtitle

Harvey Pass

Meta Tag

Speaker Harvey Pass

Topic Early-Stage NSCLC: Changing Paradigms & Outcomes

Keywords

recurrence risk assessment

stage I non-small cell lung cancer

adenocarcinoma grading system

serum proteomic testing

stratification of recurrence risk

personalized treatment protocols

mass spectrometry

circulating proteome

machine learning

ternary recurrence risk stratification test